fashion -WSS

fashion

author：leisure time 2025-10-01 02:15:15 - browse：4

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FDA scientists endorse Pfizer/BioNTech Covid

WSS

Heart disease in astronauts blamed on cosmic radiation

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Medicare slashes safety net hospital payments by nearly $1 billion

New report analyzes digital physical therapy solutions' effectiveness

Report captures long Covid’s disabling effects and policy challenges

How to ethically and practically extend health care to all

knowledge

fashion

Wikipedia

Medicare details structure of new drug price negotiation program

ALS patient reclaims some autonomy thanks to wearable 'robot'

The high cost of giving birth even with insurance

Stephen Quake on the Chan Zuckerberg quest to conquer disease

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

5 takeaways from STAT's examination of Zynex Medical

State Dept. review finds Biden bears some blame for Afghanistan failures

When waiting feels immoral: Empathy in the emergency department

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Virtual Event: ASCO Recap, Live!

leisure time

'Null' research findings aren't empty of meaning. Let's publish them

Pharma showers House GOP doctor with campaign cash

A controversial new treatment promises to make little people taller

Moderna says combo Covid

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

H.R. 3 is the wrong path to lower drug costs

entertainment

knowledge

hotspot

focus